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Established Facts
•	 Fibroblasts of triple A patients exhibit increased oxidative stress in vitro that might be related to pro-
gressive neurodegeneration.
•	 N-acetylcysteine protects renal function in patients with kidney injuries associated with increased 
oxidative stress and improved viability of AAAS-knockdown adrenal and neuronal cells in vitro.
Novel Insights
•	 Increased oxidative stress is reported in vivo in a boy with triple A syndrome assessed by increased 
thiobarbituric acid reactive substances (TBARS) and LDL oxidation.
•	 Oral administration of N-acetylcysteine was safe and capable of decreasing TBARS, reducing the sus-
ceptibility of LDL to oxidation and improving antioxidant protection of HDL. Long-term effects on 
neurodegenerative manifestations are still unknown.
DOI: 10.1159/000465520
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Abstract
Introduction: Triple A syndrome (AAAS) is a rare autosomal 
recessive disorder characterized by alacrima, achalasia, 
ACTH-resistant adrenal insufficiency, autonomic dysfunc-
tion, and progressive neurodegeneration. Increased oxida-
tive stress, demonstrated in patients’ fibroblasts in vitro, may 
be a central disease mechanism. N-acetylcysteine protects 
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renal function in patients with kidney injuries associated 
with increased oxidative stress and improves viability of 
AAAS-knockdown adrenal cells in vitro. Patient and Results: 
A boy diagnosed with AAAS presented with short stature 
and increased oxidative stress in vivo assessed by increased 
thiobarbituric acid reactive substances (TBARS), which are 
markers of lipid peroxidation, and by the susceptibility of 
LDL to oxidation and the capacity of HDL to prevent it. 
A homozygous missense germline mutation (c.523G>T, 
p.Val175Phe) in AAAS was identified. N-acetylcysteine (600 
mg orally, twice daily) decreased oxidative stress but did not 
change the patient’s growth pattern. Conclusions: An in-
crease in oxidative stress is reported for the first time in vivo 
in an AAAS patient. N-acetylcysteine was capable of decreas-
ing TBARS levels, reducing the susceptibility of LDL to oxida-
tion and improving the antioxidant role of HDL. The long-
term effect of antioxidant treatment should be evaluated to 
determine the real benefit for the prevention of the degen-
erative process in AAAS. © 2017 S. Karger AG, Basel
Introduction
Triple A syndrome is a rare autosomal recessive disor-
der mainly characterized by the triad of alacrima, achala-
sia, and ACTH-resistant adrenal insufficiency in combi-
nation with autonomic dysfunction and progressive neu-
rodegeneration. The disorder is caused by homozygous 
and compound heterozygous mutations in the AAAS 
gene. This gene is located at chromosome 12q13 and en-
codes the nucleoporin ALADIN [1]. 
Patients’ fibroblasts exhibit increased oxidative stress 
in vitro that might be related to progressive neurodegen-
eration [2, 3]. Previous studies have shown that N-acetyl-
cysteine (NAC) protects renal function in rats and hu-
mans with kidney injuries associated with increased oxi-
dative stress [4–6]. Prasad et al. [7] demonstrated an 
improvement in the viability of AAAS-knockdown adre-
nal and neuronal cells after treatment with NAC in vitro. 
We report the preliminary treatment response using the 
antioxidant NAC in a pediatric patient with triple A syn-
drome and increased oxidative stress in plasma. Oxida-
tive stress in vivo was assessed by measuring thiobarbitu-
ric acid reactive substances (TBARS) in plasma, which are 
markers of lipid peroxidation, by measuring reduced glu-
tathione (GSH), an intracellular thiol whose main role is 
to protect cells from oxidative damage [8], and by the sus-
ceptibility of LDL to oxidation and the capacity of HDL 
to prevent it [9].
Case Report
A boy born to consanguineous parents presented in infancy at 
a local hospital with jaundice, severe anemia, neurodevelopmental 
delay, repeated otitis, and elevated hepatic enzymes. By the age of 
6–7 months, repeated vomiting and a decline in growth velocity 
were noted. He was submitted to gastroduodenal serigraphy, and 
the diagnosis of gastroesophageal reflux was made. Despite sev-
eral treatments, he had many hospital admissions due to episodes 
of otitis, diarrhea, and bronchitis. 
At 3 years of age, investigation of abdominal pain, hypoglyce-
mia, and seizures led to the diagnosis of isolated primary cortisol 
deficiency, and replacement with glucocorticoid was started. De-
spite improvement of the abdominal pain, the patient continued 
vomiting and underwent a swallowing videogram, which was sug-
gestive of achalasia. The lower esophageal sphincter was endo-
scopically dilated twice and he underwent Heller’s cardiomyoto-
my. Since the beginning of the follow-up, the patient presented 
with severe short stature, with bone age delayed by 3 years, but no 
signs of malnutrition (serum albumin 5.0 g/dL and hemoglobin 
13.6 g/dL before surgery). There was not much improvement in 
his height after the correction of achalasia (before surgery: 109 cm, 
SDS –3.7; 1 year after surgery: 117 cm, SDS –3.17; target height: 
SDS –0.93). The Schirmer test was compatible with alacrima. 
Genetic study was approved by the Hospital Ethics Committee. 
Molecular analysis identified a homozygous missense mutation 
(c.523G>T) in exon 6 of AAAS gene resulting in a change of valine 
at amino acid position 175 into phenylalanine (p.Val175Phe). His 
unaffected mother presented the same mutation in the heterozy-
gous state. 
Based on previous studies with NAC in chronic renal failure 
models and considering the safety of this drug we proposed to the 
patient’s mother that the patient should be treated with NAC. This 
was accepted, and a formal term of consent was signed.
Methods
Thiobarbituric Acid Reactive Substances 
Plasma levels of TBARS were determined using the thiobarbi-
turic acid assay. In brief, a 0.2-mL plasma sample was diluted in 0.8 
mL of distilled water. Immediately thereafter, 1 mL of 17.5% tri-
chloroacetic acid was added. Following the addition of 1 mL 
of 0.6% thiobarbituric acid, pH 2, the sample was placed in a boil-
ing water bath for 15 min, after which it was allowed to cool. Subse-
quently, 1 mL of 70% trichloroacetic acid was added, and the mix-
ture was incubated for 20 min. The sample was then centrifuged 
for 15 min at 2,000 rpm. The optical density of the supernatant was 
read at 534 nm against a blank reagent using a spectrophotom- 
eter. The concentration of lipid peroxidation products was calcu-
lated as malondialdehyde equivalent using a molar extinction co-
efficient for the malondialdehyde-thiobarbituric acid complex of 
1.56 × 105 mol−1 cm−1. Plasma levels of TBARS were expressed in 
nmol/mL [10]. We have used plasma samples of 43 healthy children 
(1.60 ± 0.04 nmol/mL) as a control for plasma TBARS levels [11]. 
Reduced GSH
Reduced GSH was determined in total blood by the method of 
Sedlak and Lindsay [12]. Whole blood was processed by the addi-
tion of 4 volumes of ice-cold 5% (W/V) metaphosphoric acid (Sig-
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ma-Aldrich, Germany) and centrifuged at 14,000 g for 3 min. This 
assay consists of the supernatants of the total blood reacting with 
Ellman’s reagent to produce a yellow pigment measured spectro-
photometrically at 412 nm. The GSH was quantified with a stan-
dard curve and reported as µmol/mL [13].
LDL Oxidation
To test the ability of the patient’s HDL in inhibiting LDL oxida-
tion, pooled LDL (40 mg protein) from healthy donors (C-LDL) 
was incubated with CuSO4 (10 mmol/L final concentration) at 
37  ° C in the presence of HDL (80 mg protein) isolated from the 
patient prior and after NAC treatment. In another set of incuba-
tions, the susceptibility of the patient’s LDL to oxidation was ana-
lyzed by incubating pooled HDL from healthy donors (C-HDL) 
with the patient’s LDL (isolated prior and after NAC treatment) in 
the presence of CuSO4.
The kinetics of conjugated diene formation was monitored at 
234 nm for 4 h at 3-min intervals in order to calculate the lag phase 
time (the time – in minutes – elapsed between the beginning of the 
reaction and the propagation phase) and the maximal rate of con-
jugated diene formation (Δabsorbance/time elapsed in minutes 
between the initiation phase and the maximal absorbance phase) 
according to Esterbauer et al. [14].
Results
TBARS and GSH levels demonstrated an increased ox-
idative stress in the patient’s plasma (Fig. 1). TBARS lev-
els decreased during NAC treatment (600 mg orally, twice 
daily) despite the suboptimal compliance of the patient 
during follow-up. No side effects or adverse events of 
NAC were reported during treatment. 
Before and after NAC treatment, LDL and HDL were 
obtained from the patient’s plasma after discontinuous 
density ultracentrifugation, in order to assess the suscep-
tibility of LDL oxidation as another marker of oxidative 
stress. As shown in Figure 2a, the lag time (minutes; mean 
± SEM) for C-LDL oxidation in the presence of HDL iso-
lated after NAC treatment was increased (20.6 ± 0.4) 
compared to that when incubated with HDL isolated pri-
or to treatment (19.4 ± 0.7). In addition, the susceptibil-
ity of the patient’s LDL to oxidation after NAC treatment 
was diminished as shown by the enhanced lag time (min-
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Fig. 1. TBARS and reduced GSH during 
NAC treatment. Horizontal bars indicate 
the period when the patient had a good 
compliance with NAC treatment, with a re-
duction in TBARS that was not sustained 
when the patient stopped the medication.
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Fig. 2. Assessment of the LDL oxidation be-
fore and after NAC treatment. Analyses 
were done in replicates (n = 5–6) utilizing 
HDL or LDL before and after patient treat-
ment with NAC in order to access the lag 
phase for LDL oxidation. a Lag time for C-
LDL oxidation from healthy controls in the 
presence of the patient’s HDL isolated be-
fore and after NAC treatment. b Lag time 
for conjugated diene formation indicating 
the susceptibility of the patient’s LDL to 
oxidation before after NAC treatment in 
the presence of HDL from healthy controls 
(C-HDL).
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utes; mean ± SEM) for conjugated diene formation 
(Fig. 2b: 8.8 ± 2.1 vs. 14.9 ± 1.9).
The short stature of the patient persisted even with the 
decrease in oxidative stress and the spontaneous onset of 
puberty. Treatment with growth hormone 0.15 U/kg/day 
was started, with little improvement of height SDS (height 
before rhGH 124.0 cm, SDS –2.89; height 1 year after 
rhGH 129.6 cm, SDS –2.55). During follow-up, the pro-
gression of puberty was slow. 
Discussion 
Reactive oxygen species (ROS) are produced primarily 
by mitochondria as a byproduct of normal metabolism 
during the conversion of molecular oxygen to water. Cells 
have several antioxidant defense mechanisms, such as su-
peroxide dismutase and GSH. Oxidative stress is gener-
ated when an imbalance exists between production of ox-
idants and the antioxidative defense. ROS excess may 
damage cellular macromolecules with DNA oxidation 
[15]. The adrenal cortex is a tissue with high metabolic 
demand and high turnover of lipids by the mitochondria 
during steroidogenesis and is particularly susceptible to 
oxidative stress caused by the excessive ROS production. 
Triple A syndrome is a rare, autosomal recessive cause of 
adrenal failure that affects steroidogenesis because of the 
imbalance in redox homeostasis, impairing the function 
of several enzymes such as CYP17A1, CYP21A2, and 
POR [3]. In about 70% of cases, the defect is due to muta-
tions in the AAAS gene [1]. Its product, the ALADIN pro-
tein, has a role in preventing DNA damage of the cell and 
consecutive apoptosis under oxidative stress [3]. Dermal 
fibroblasts of triple A patients have higher basal intracel-
lular ROS and are more sensitive to oxidative stress than 
wild-type fibroblasts [2]. NAC, which is a precursor of L-
cysteine and reduced GSH, has been extensively studied 
as an antioxidant. NAC is a source of sulfhydryl groups 
in cells and a scavenger of free radicals, such as hydroxyl 
radicals and hydrogen peroxide. In addition, NAC can 
triple endothelial nitric oxide synthase expression as well 
as increase nitric oxide bioavailability [16, 17]. Several 
studies using animal and human models with increased 
oxidative stress showed benefits of NAC when compared 
to placebo [18, 19].
Our patient was treated with NAC administration by 
oral route, because it is noninvasive and has been proved 
to be as effective as the intravenous route [16]. No side 
effects were detected during follow-up. We employed a 
NAC dose of 600 mg twice daily based on a previous study 
by Tepel et al. [4] who demonstrated a reduction in car-
diovascular events in patients with end-stage renal failure 
on this dose of NAC. ROS are unstable compounds with 
a half-live of seconds; thus, indirect methods have been 
developed to measure lipoperoxidation products, such as 
TBARS, or antioxidant products, such as GSH. In the pre-
sented case, NAC was safe and managed to reduce TBARS 
levels as expected and enhanced the HDL protection 
against LDL oxidation. This finding shows that NAC in-
creased the antioxidant property of HDL minimizing 
LDL oxidation. In addition, NAC decreased the suscepti-
bility of LDL to oxidation [20]. Oxidized LDL reflects ox-
idative stress, and its concentration in plasma is related to 
chronic inflammation and development of several chron-
ic diseases [20, 21]. In conclusion, we present the first in 
vivo study of ROS reduction by NAC treatment in a boy 
with triple A syndrome. The long-term effect of this treat-
ment should be evaluated to determine its real benefit for 
the prevention of the degenerative process in triple A syn-
drome.
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